- Home
- QNRX
as 01-17-2025 4:00pm EST
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | KFAR SABA |
| Market Cap: | 5.3M | IPO Year: | N/A |
| Target Price: | $4.00 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.42 - $6.18 | Next Earning Date: | 03-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Quoin Pharmaceuticals Ltd. (QNRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dunn Gordon | QNRX | Chief Financial Officer | Dec 23 '24 | Buy | $0.45 | 122,221 | $54,999.45 | 151,077 | |
| Myers Michael | QNRX | Chief Executive Officer | Dec 23 '24 | Buy | $0.45 | 555,556 | $250,000.20 | 602,808 | |
| Carter Denise P. | QNRX | Chief Operating Officer | Dec 23 '24 | Buy | $0.45 | 555,556 | $250,000.20 | 602,648 | |
| Culverwell Anthony James | QNRX | Director | Dec 23 '24 | Buy | $0.45 | 100,000 | $45,000.00 | 100,317 |
Latest Quoin Pharmaceuticals Ltd. News
QNRX Breaking Stock News: Dive into QNRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Quoin Pharmaceuticals Announces Further Positive Clinical Data from Ongoing Pediatric Netherton Syndrome Study
GlobeNewswire
11 days ago
PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials
GlobeNewswire
13 days ago
Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study
MT Newswires
22 days ago
Quoin Pharmaceuticals Insider Bought Shares Worth $250,000, According to a Recent SEC Filing
MT Newswires
a month ago
Quoin Pharmaceuticals Prices $6.8 Million Equity Offering -- Shares Fall
GlobeNewswire
a month ago
Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering
GlobeNewswire
a month ago
Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study
GlobeNewswire
a month ago
Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies
Compare QNRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "QNRX Quoin Pharmaceuticals Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.